ArticleCancer medicine2026
Trends in the Adoption of MRI Associated Biopsy for Active Surveillance Within the First Year After Localized Prostate Cancer Diagnosis: A SEER-Medicare Cohort Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundActive surveillance strategies have evolved to incorporate new technologies, such as MRI. However, trends in the adoption of this technology within the first year after cancer diagnosis as part of the initial active surveillance activity remain unclear.
methodsUsing SEER-Medicare data, this cross-sectional study examined trends in the use of various active surveillance strategies, including MRI associated biopsy, within the first year of cancer diagnosis among men diagnosed with localized prostate cancer between 2010-2011 and 2018-2019. Patients were stratified by Gleason score, age, and race/ethnicity.
resultsAmong patients without active treatment in the first year after localized prostate cancer diagnosis, the unadjusted proportion undergoing MRI associated biopsy as an active surveillance strategy increased from 0.8% in 2010-2011 to 3.16% in 2018-2019 for GS ≤ 6, and from 0.7% to 4.69% over the same period for GS ≥ 7. Patients aged 66-74 had consistently higher probabilities of undergoing MRI associated biopsy than patients aged 75+, and non-Hispanic White patients had consistently higher probabilities of undergoing MRI associated biopsy than non-Hispanic Black.
conclusionsThe use of new active surveillance strategies, such as MRI associated biopsy, were low in overall use but increased over time from 2010-2011 to 2018-2019, with notable differences across patient subgroups defined by age and race/ethnicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.